LLY

1,141.85

+4.79%↑

JNJ

231.01

-0.17%↓

ABBV

218.68

+2.43%↑

UNH

386.88

+1.29%↑

MRK

120.62

-0.54%↓

LLY

1,141.85

+4.79%↑

JNJ

231.01

-0.17%↓

ABBV

218.68

+2.43%↑

UNH

386.88

+1.29%↑

MRK

120.62

-0.54%↓

LLY

1,141.85

+4.79%↑

JNJ

231.01

-0.17%↓

ABBV

218.68

+2.43%↑

UNH

386.88

+1.29%↑

MRK

120.62

-0.54%↓

LLY

1,141.85

+4.79%↑

JNJ

231.01

-0.17%↓

ABBV

218.68

+2.43%↑

UNH

386.88

+1.29%↑

MRK

120.62

-0.54%↓

LLY

1,141.85

+4.79%↑

JNJ

231.01

-0.17%↓

ABBV

218.68

+2.43%↑

UNH

386.88

+1.29%↑

MRK

120.62

-0.54%↓

Home・Akciju saraksts・Myriad Genetics Inc

Myriad Genetics Inc

Atvērts

SektorsVeselības aprūpe

4.1 4.86

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.84

Max

4.15

Galvenie mērījumi
By Trading Economics
Ienākumi	-26M -34M
Pārdošana	-9.4M 200M
EPS	-0.09
Peļņas marža	-17.016
Darbinieki	2,700
EBITDA	43M -18M

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	+94.81% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-106M 361M
Iepriekšējā atvēršanas cena	-0.76
Iepriekšējā slēgšanas cena	4.1

Ziņu noskaņojums

By Acuity

46%

54%

116 / 344 Rangs Healthcare

Myriad Genetics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 27. maijs 21:33 UTC

Peļņas

Correction to Salesforce 1Q Sales, Profit Rise Article

2026. g. 27. maijs 21:00 UTC

Iegādes, apvienošanās, pārņemšana

HCA Healthcare Agrees to Buy The College of Health Care Professions

2026. g. 27. maijs 20:18 UTC

Peļņas

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

2026. g. 27. maijs 23:49 UTC

Tirgus saruna

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

2026. g. 27. maijs 23:39 UTC

Tirgus saruna

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

2026. g. 27. maijs 23:34 UTC

Tirgus saruna

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

2026. g. 27. maijs 23:34 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 27. maijs 23:08 UTC

Tirgus saruna

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

2026. g. 27. maijs 22:21 UTC

Tirgus saruna

Salesforce Lays Out AI Monetization Strategy -- Market Talk

2026. g. 27. maijs 21:29 UTC

Karstas akcijas

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

2026. g. 27. maijs 21:08 UTC

Peļņas

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

2026. g. 27. maijs 21:02 UTC

Peļņas

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

2026. g. 27. maijs 20:59 UTC

Iegādes, apvienošanās, pārņemšana

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

2026. g. 27. maijs 20:55 UTC

Peļņas

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

2026. g. 27. maijs 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 27. maijs 20:48 UTC

Peļņas

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

2026. g. 27. maijs 20:45 UTC

Peļņas

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

2026. g. 27. maijs 20:34 UTC

Iegādes, apvienošanās, pārņemšana

Webster Financial Stockholders Approve Sale to Banco Santander

2026. g. 27. maijs 20:32 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

2026. g. 27. maijs 20:32 UTC

Iegādes, apvienošanās, pārņemšana

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

2026. g. 27. maijs 20:32 UTC

Iegādes, apvienošanās, pārņemšana

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

2026. g. 27. maijs 20:30 UTC

Peļņas

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

2026. g. 27. maijs 20:30 UTC

Iegādes, apvienošanās, pārņemšana

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

2026. g. 27. maijs 20:22 UTC

Peļņas

Salesforce Stock Slides on Mixed Results -- Barrons.com

2026. g. 27. maijs 20:16 UTC

Peļņas

Salesforce Stock Slides on Mixed Results -- Barrons.com

2026. g. 27. maijs 20:13 UTC

Peļņas

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

2026. g. 27. maijs 20:13 UTC

Peļņas

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

2026. g. 27. maijs 20:13 UTC

Peļņas

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

2026. g. 27. maijs 20:12 UTC

Peļņas

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

2026. g. 27. maijs 20:12 UTC

Peļņas

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Salīdzinājums

Cenas izmaiņa

Myriad Genetics Inc Prognoze

Cenas mērķis

By TipRanks

94.81% augšup

Prognoze 12 mēnešiem

Vidējais 7.5 USD 94.81%

Augstākais 10 USD

Zemākais 5.5 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Myriad Genetics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Myriad Genetics Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

116 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.